Cogent Biosciences, Inc. (COGT) stock
COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$27.44−1.12 (-3.92%)
Close on Nov 16, 2026Market cap $4.76BP/E –Yield –
Cogent Biosciences operating margin
Operating margin is operating income as a percentage of revenue.
Cogent Biosciences's operating margin for the twelve months ending Dec 31, 2020 was -1044.3%. For fiscal 2020 it was -1044.3%, against -143.0% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | -1044.3% | −901.3 |
| FY2019 | Dec 31, 2019 | -143.0% | +226.9 |
| FY2018 | Dec 31, 2018 | -369.9% | −57.1 |
| FY2017 | Dec 31, 2017 | -312.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2020 | Sep 30, 2020 | -18333.0% | −17153.0 |
| Q2 FY2020 | Jun 30, 2020 | -1402.1% | −1066.2 |
| Q1 FY2020 | Mar 31, 2020 | -87.3% | +300.5 |
| Q4 FY2019 | Dec 31, 2019 | 14.7% | +251.3 |
| Q3 FY2019 | Sep 30, 2019 | -1180.0% | −662.3 |
| Q2 FY2019 | Jun 30, 2019 | -335.9% | +230.7 |
| Q1 FY2019 | Mar 31, 2019 | -387.8% | −73.2 |
| Q4 FY2018 | Dec 31, 2018 | -236.6% | +87.4 |
| Q3 FY2018 | Sep 30, 2018 | -517.7% | −210.1 |
| Q2 FY2018 | Jun 30, 2018 | -566.6% | −276.4 |
| Q1 FY2018 | Mar 31, 2018 | -314.7% | +17.5 |
| Q4 FY2017 | Dec 31, 2017 | -324.1% | – |
| Q3 FY2017 | Sep 30, 2017 | -307.6% | – |
| Q2 FY2017 | Jun 30, 2017 | -290.2% | – |
| Q1 FY2017 | Mar 31, 2017 | -332.2% | – |
See a number that looks wrong?